Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests. Paxlovid ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID-19 who have mild symptoms and face a high risk of hospitalization.

It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older ...

What do you do? Specifically, what's the role of antivirals? You might have heard about a drug called Paxlovid. Well, Paxlovid is a pill that you take by mouth, as opposed to some other therapies ...

THURSDAY, March 6, 2025 (HealthDay News) -- The antiviral drug Paxlovid may not offer much protection against COVID-related hospitalizations or deaths for vaccinated older adults after all.

Treatment with Paxlovid in older adults did not appear to make a difference in whether or not they were hospitalized because of COVID-19. Over a 9-month time span starting in April 2022 ...

The U.S. Government Patient Assistance Program (USG PAP), operated by Pfizer, will provide eligible Medicare beneficiaries with free Paxlovid access until December 31, 2025. This program is also ...